Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects
- PMID: 11687611
- PMCID: PMC60863
- DOI: 10.1073/pnas.221452198
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects
Abstract
The risks and benefits of structured treatment interruption (STI) in HIV-1-infected subjects are not fully understood. A pilot study was performed to compare STI with continuous highly active antiretroviral therapy (HAART) in chronic HIV-1-infected subjects with HIV-1 plasma RNA levels (VL) <400 copies per ml and CD4(+) T cells >400 per microl. CD4(+) T cells, VL, HIV-1-specific neutralizing antibodies, and IFN-gamma-producing HIV-1-specific CD8(+) and CD4(+) T cells were measured in all subjects. STIs of 1-month duration separated by 1 month of HAART, before a final 3-month STI, resulted in augmented CD8(+) T cell responses in all eight STI subjects (P = 0.003), maintained while on HAART up to 22 weeks after STI, and augmented neutralization titers to autologous HIV-1 isolate in one of eight subjects. However, significant decline of CD4(+) T cell count from pre-STI level, and VL rebound to pre-HAART baseline, occurred during STI (P = 0.001 and 0.34, respectively). CD4(+) T cell counts were regained on return to HAART. Control subjects (n = 4) maintained VL <400 copies per ml and stable CD4(+) T cell counts, and showed no enhancement of antiviral CD8(+) T cell responses. Despite increases in antiviral immunity, no control of VL was observed. Future studies of STI should proceed with caution.
Figures


Similar articles
-
Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.Int J Infect Dis. 2010 Jan;14(1):e34-40. doi: 10.1016/j.ijid.2009.03.003. Epub 2009 May 20. Int J Infect Dis. 2010. PMID: 19467895 Clinical Trial.
-
The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.AIDS. 2001 Jun 15;15(9):F29-40. doi: 10.1097/00002030-200106150-00002. AIDS. 2001. PMID: 11416735 Clinical Trial.
-
Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.AIDS Res Hum Retroviruses. 2004 Dec;20(12):1283-8. doi: 10.1089/aid.2004.20.1283. AIDS Res Hum Retroviruses. 2004. PMID: 15650419
-
Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.Ann Intern Med. 2000 Sep 19;133(6):447-54. doi: 10.7326/0003-4819-133-6-200009190-00013. Ann Intern Med. 2000. PMID: 10975963 Review.
-
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.Curr Med Chem. 2005;12(15):1705-19. doi: 10.2174/0929867054367211. Curr Med Chem. 2005. PMID: 16029143 Review.
Cited by
-
Cellular reservoirs of HIV-1 and their role in viral persistence.Curr HIV Res. 2008 Sep;6(5):388-400. doi: 10.2174/157016208785861195. Curr HIV Res. 2008. PMID: 18855649 Free PMC article. Review.
-
Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13377-8. doi: 10.1073/pnas.212518999. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370421 Free PMC article. Review. No abstract available.
-
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. doi: 10.1073/pnas.202372199. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370434 Free PMC article. Clinical Trial.
-
Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire.Blood. 2006 Mar 15;107(6):2373-83. doi: 10.1182/blood-2005-04-1636. Epub 2005 Dec 1. Blood. 2006. PMID: 16322475 Free PMC article.
-
CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.AIDS Res Hum Retroviruses. 2008 Aug;24(8):1047-66. doi: 10.1089/aid.2008.0059. AIDS Res Hum Retroviruses. 2008. PMID: 18724805 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials